Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEB-1837
- Development stage
- Preclinical
- Lead developer
- Mebias Discovery
- Modality
- Small Molecules
01
Overview
MEB-1837 is a small molecule drug candidate developed by Mebias Discovery. It acts as a modulator of the sphingosine 1-phosphate receptor subtype 1 (S1PR1), also known as Sphingosine 1-phosphate receptor Edg-1. The drug is being investigated for its potential to treat neuropathic pain, specifically neuralgia, by leveraging pathway-selective (biased) G-protein-coupled receptor (GPCR) signaling to maximize therapeutic effects while minimizing adverse effects commonly associated with GPCR-targeting drugs. As of March 2025, MEB-1837 remains in preclinical development and has not entered clinical trials or received regulatory approval[1][3][5].
02
Targets
EDG1 (Sphingosine-1-phosphate receptors)
Beyond the preview
Go deeper on MEB-1837.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEB-1837.